UNLABELLED: What's known on the subject? and What does the study add? The degree of comorbidity significantly affects the course of patients with bladder cancer undergoing radical cystectomy (RC). To our knowledge this is the first study comparing four different comorbidity indices in patients undergoing RC for urothelial carcinoma to assess the best clinical predictors for 90-day perioperative mortality. We concluded that the ASA score should be the method of choice, as it showed a predictive ability superior to that of ECOG and CCI, and is much easier to generate than the ACE-27. OBJECTIVE: To evaluate which of the following among the Adult Comorbidity Evaluation-27 (ACE-27), the Charlson Comorbidity Index (CCI), the Eastern Cooperative Oncology Group performance status (ECOG) and the American Society of Anesthesiologists (ASA) comorbidity scores correlate best with perioperative mortality after radical cystectomy (RC) for urothelial carcinoma (UC) of the bladder. PATIENTS AND METHODS: A study was carried out on 555 unselected consecutive patients without neoadjuvant chemotherapy who underwent RC for UC of the bladder from 2000 to 2010 at one of two institutions. Patients' medical records were reviewed retrospectively. We established a defined binary linear progression model based on clinical variables to predict perioperative mortality <90 days after RC (90PM). To this model we added, individually, the comorbidity indices ACE-27, CCI, ECOG, and ASA to assess their predictive capacity regarding 90PM. RESULTS: The overall 90PM was 7.9%. Age (P = 0.01) and clinical distant metastatic tumour stage (P = 0.002) were independent predictors for 90PM in the multivariate analysis. Each of the four investigated comorbidity indices was able to significantly increase the predictive capacity of the basic model: ECOG +13.5%, (odds ratio [OR]: 1.61, P = 0.036; area under the curve [AUC] 74.7), ASA Score +28.3% (OR: 2.19, P = 0.004; AUC 76.1), Charlson Index +12.3% (OR: 1.31, P = 0.047; AUC 73.8) and ACE-27 + 29.8% (OR: 1.72, P = 0.004; AUC 76.1). CONCLUSIONS: ASA and ACE-27 show a nearly identical clinical predictive value for perioperative mortality. Both scores could be considered for clinical practice. With regard to ease of generation and availability, the ASA score can be regarded as the best instrument.
UNLABELLED: What's known on the subject? and What does the study add? The degree of comorbidity significantly affects the course of patients with bladder cancer undergoing radical cystectomy (RC). To our knowledge this is the first study comparing four different comorbidity indices in patients undergoing RC for urothelial carcinoma to assess the best clinical predictors for 90-day perioperative mortality. We concluded that the ASA score should be the method of choice, as it showed a predictive ability superior to that of ECOG and CCI, and is much easier to generate than the ACE-27. OBJECTIVE: To evaluate which of the following among the Adult Comorbidity Evaluation-27 (ACE-27), the Charlson Comorbidity Index (CCI), the Eastern Cooperative Oncology Group performance status (ECOG) and the American Society of Anesthesiologists (ASA) comorbidity scores correlate best with perioperative mortality after radical cystectomy (RC) for urothelial carcinoma (UC) of the bladder. PATIENTS AND METHODS: A study was carried out on 555 unselected consecutive patients without neoadjuvant chemotherapy who underwent RC for UC of the bladder from 2000 to 2010 at one of two institutions. Patients' medical records were reviewed retrospectively. We established a defined binary linear progression model based on clinical variables to predict perioperative mortality <90 days after RC (90PM). To this model we added, individually, the comorbidity indices ACE-27, CCI, ECOG, and ASA to assess their predictive capacity regarding 90PM. RESULTS: The overall 90PM was 7.9%. Age (P = 0.01) and clinical distant metastatic tumour stage (P = 0.002) were independent predictors for 90PM in the multivariate analysis. Each of the four investigated comorbidity indices was able to significantly increase the predictive capacity of the basic model: ECOG +13.5%, (odds ratio [OR]: 1.61, P = 0.036; area under the curve [AUC] 74.7), ASA Score +28.3% (OR: 2.19, P = 0.004; AUC 76.1), Charlson Index +12.3% (OR: 1.31, P = 0.047; AUC 73.8) and ACE-27 + 29.8% (OR: 1.72, P = 0.004; AUC 76.1). CONCLUSIONS:ASA and ACE-27 show a nearly identical clinical predictive value for perioperative mortality. Both scores could be considered for clinical practice. With regard to ease of generation and availability, the ASA score can be regarded as the best instrument.
Authors: M Gierth; R Mayr; A Aziz; S Krieger; B Wullich; A Pycha; M Lodde; U Salvadori; J Bründl; H M Fritsche; F Hofstädter; M T Pawlik; W Otto; M May; M Burger; S Denzinger Journal: J Cancer Res Clin Oncol Date: 2015-04-02 Impact factor: 4.553
Authors: Atiqullah Aziz; Michael Gierth; Michael Rink; Marianne Schmid; Felix K Chun; Roland Dahlem; Florian Roghmann; Rein-Jüri Palisaar; Joachim Noldus; Jörg Ellinger; Stefan C Müller; Armin Pycha; Thomas Martini; Christian Bolenz; Rudolf Moritz; Edwin Herrmann; Bastian Keck; Bernd Wullich; Roman Mayr; Hans-Martin Fritsche; Maximilian Burger; Patrick J Bastian; Christian Seitz; Sabine Brookman-May; Evanguelos Xylinas; Shahrokh F Shariat; Margit Fisch; Matthias May Journal: World J Urol Date: 2015-05-07 Impact factor: 4.226
Authors: M Gierth; A Aziz; H M Fritsche; M Burger; W Otto; F Zeman; M T Pawlik; E Hansen; M May; S Denzinger Journal: World J Urol Date: 2014-02-08 Impact factor: 4.226
Authors: Roman Mayr; Hans-Martin Fritsche; Florian Zeman; Marieke Reiffen; Leopold Siebertz; Christoph Niessen; Armin Pycha; Bas W G van Rhijn; Maximilian Burger; Michael Gierth Journal: World J Urol Date: 2018-03-08 Impact factor: 4.226
Authors: Dharam Kaushik; Igor Frank; Manuel S Eisenberg; John C Cheville; Robert Tarrell; Prabin Thapa; R Houston Thompson; Stephen A Boorjian Journal: World J Urol Date: 2013-12-21 Impact factor: 4.226
Authors: Stephen B Williams; Ashish M Kamat; Karim Chamie; Michael Froehner; Manfred P Wirth; Peter N Wiklund; Peter C Black; Gary D Steinberg; Stephen A Boorjian; Sia Daneshmand; Peter J Goebell; Kamal S Pohar; Shahrokh F Shariat; George N Thalmann Journal: Eur Urol Oncol Date: 2018-06-06